LUMINA Study Revels Radiotherapy is Not Needed for Some Luminal A Breast Cancers
June 7th 2022According to Timothy J. Whelan, MD, FASCO, radiotherapy is an inconvenient treatment. It can last daily for up to 5 weeks and it is a costly therapy. Study results shows that is can safely be omitted in the treatment of some patients with luminal A breast cancers.
Durable Response Elicited With CLDN18.2-Directed CAR T-cell Therapy in Gastrointestinal Cancers
June 5th 2022Treatment with a Claudin18.2–specific chimeric antigen receptor T-cell therapy has demonstrated either a response or stable disease in patients with heavily pretreated advanced gastric and pancreatic adenocarcinoma.
DESTINY-Breast03 Update Reinforces Safety of Trastuzumab Deruxtecan in Metastatic Breast Cancer
June 4th 2022A safety follow-up analysis of the randomized phase 3 DESTINY-Breast03 study reinforced the risk-benefit profile of trastuzumab deruxtecan compared with trastuzumab emtansine in patients with HER2-positive unresectable or metastatic breast cancer
Adjuvant Everolimus Reduces Risk of Recurrence or Death in High-Risk RCC
June 4th 2022Results from the phase 3 EVEREST trial presented during the 2022 ASCO Annual Meeting reveal the relapse-free survival advantage of using adjuvant everolimus over placebo in patient with high-risk renal cell carcinoma.
FDA Grants Fast Track Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers
January 18th 2022A fast track designation has been granted to CYNK-101 in combination with standard frontline chemotherapy, trastuzumab, and pembrolizumab for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Use of Axi-Cel in Previously Excluded LBCL Populations Supported by Real-World Evidence
December 13th 2021While Axicabtagene ciloleucel demonstrated favorable efficacy in elderly patients and those with other comorbidities with large B-cell lymphoma, adverse events were common in some of these populations.
Impressive Results Continue With Updated Data on bb21217 in Multiple Myeloma
December 11th 2019In the phase I CRB-402 study, patients with heavily pretreated relapsed/refractory multiple myeloma and minimal residual disease negativity had very good partial responses to the anti-BCMA CAR T cell therapy bb21217, according to updated results presented at the 2019 American Society of Hematology Annual Meeting.<br />
Navitoclax Shows Activity in Ruxolitinib-Resistant Patients With Myelofibrosis
December 10th 2019Patients with primary or secondary myelofibrosis who developed resistance to ruxolitinib in the frontline setting, showed clinically meaningful spleen responses and improvements in symptoms with the addition of navitoclax to ruxolitinib, according to findings from a phase II study presented at the 2019 ASH Annual Meeting.
CC-486 Maintenance Extends OS in Older Patients With Acute Myeloid Leukemia
December 10th 2019An extended media overall survival of 9.9 months was achieved with CC-486 maintenance treatment compared with placebo for older patients with acute myeloid leukemia in first remission, according to findings from the phase III QUAZAR AML-001 trial presented at the 2019 American Society of Hematology Annual Meeting.<br /> <br />
FDA Submission for KTE-X19 Planned After High CR Rates Were Observed in MCL
December 10th 2019Patients with relapsed/refractory mantle cell lymphoma experienced a 67% complete remission rate and an objective response rate of 93% after treatment with the anti-CD19 CAR T-cell therapy KTE-X19, according to findings from the phase II ZUMA-2 study presented at the 2019 American Society of Hematology ASH Annual Meeting.
Zanubrutinib Highly Effective in CLL/SLL, Despite Presence of High-Risk Cytogenetics
December 9th 2019In the SEQUOIA trial, zanubrutinib, a Bruton’s tyrosine kinase inhibitor, showed continued high overall response rates for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, regardless of deletion 17p status, according to findings presented at the American Socitey of Hematology Annual Meeting and Exposition.
LOXO-305 Shows High Efficacy in Patient With Heavily Pretreated B-cell Malignancies
December 9th 2019Treatment with LOXO-305 prompted responses from more than half of patients with heavily pretreated B-cell malignancies, including patients with resistance or intolerance to other BTK inhibitors or BCL2 inhibitors, according to findings from the phase I/II BRUIN trial presented at the 2019 American Society of Hematology Annual Meeting and Exposition.
Triplet Therapy Induced CR in R/R CLL
December 9th 2019In a phase I/II dose escalation study, there was a complete remission rate of 44% in patients with relapsed/refractory chronic lymphocytic leukemia receiving umbralisib, ublituximab, and venetoclax, according to findings presented at the 2019 ASH Annual Meeting.
Preclinical Evidence Generates Buzz Around Novel Off-the-Shelf CAR NK Therapy
December 7th 2019A multi-antigen off-the-shelf chimeric antigen receptor natural killer cell therapy has been included in the ASH annual meeting spotlight due to exciting preclinical evidence. An investigational new drug application was approved in September 2019 for the therapy, labeled as FT596, developed by Fate Therapeutics, and human trials are scheduled to start in the first quater of 2020.
Wealth of Options Available for Adjuvant Melanoma Therapy
November 8th 2019Immunotherapies and targeted therapies have greatly impacted the treatment of advanced melanoma and are beginning to make their way into earlier settings, with FDA approvals for adjuvant therapies and studies ongoing in the neoadjuvant space, according to a presentation by Jeffrey S. Weber, MD, PhD, at the <em>37th Annual</em> CFS.
Novel Combinations Represent Next Phase for Adult ALL
November 7th 2019A number of promising biologic therapies are beginning to transform the treatment of adult patients with acute lymphoblastic leukemia, with the greatest potential seen with blinatumomab and inotuzumab ozogamicin in combination with chemotherapy, according to a presentation by Hagop M. Kantarjian, MD, at the 37th Annual CFS.<br />
More Immunotherapy Regimens in NSCLC Highlight the Importance of Biomarkers
October 8th 2019The wealth of new data available for the treatment of patients with non–small cell lung cancer has led to numerous effective immunotherapy combinations in similar patient subsets, explained Karen L. Reckamp, MD, MS. Clinical trials going forward seem to primarily focus on the combination of immunotherapeutic and targeted agents, which may result in even more options for this tumor type.
Ripretinib Significantly Improves PFS in Heavily Pretreated GIST
October 6th 2019In the phase III INVICTUS trial, ripretinib, a novel KIT and PDGFRA inhibitor, demonstrated a dramatic improvement in progression-free survival compared with placebo in heavily pretreated patients with heavily advanced gastrointestinal stromal tumors, according to data presented at the 2019 ESMO Congress.
VELIA Trial Shows Benefit for Combination of PARP Plus Chemotherapy in Ovarian Cancer
October 4th 2019Patients with high-grade serous ovarian cancer experienced a 32% reduction in the risk of progression or death with frontline combination veliparib plus carboplatin and paclitaxel followed by veliparib maintenance, according to the data from the phase III VELIA trial presented at the 2019 ESMO Congress, and simultaneously published in the New England Journal of Medicine.
Risk of Progression or Death Reduced With Ivosidenib in Advanced Cholangiocarcinoma
September 30th 2019The risk of progression or death was reduced by 63% with ivosidenib as treatment of pretreated patients with IDH1-mutant advanced cholangiocarcinoma compared with placebo, according to data from the phase III ClarIDHy study that was presented at the 2019 ESMO Congress.